

## ESMO Preceptorship on Colorectal Cancer

### Multidisciplinary management, standards of care and future perspectives

### March 27-28th 2015, SINGAPORE

#### Co-Chairs:

Jean-Yves Douillard, France  
Claus-Henning Köhne, Germany

#### Faculty:

Daniela Aust, Germany  
Michel Ducreux, France  
Hauke Lang, Germany - TBC  
Kong Hwai Loong, SG  
Mark Saunders, United Kingdom  
Francis Seow-Choen, SG

#### LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology and histoprognostic factors
- To learn about the management of patients after progression, side-effects of treatments, and in special situations many

#### Friday, 27th March 2015

<b>09:00-9:15</b>	<b>Welcome and introduction</b>	<b>JY Douillard, FR Francis Seow-Choen, SG</b>
-------------------	---------------------------------	--

<b>09:15 -10:50 95'</b>	<b>Session 1 Early colorectal cancer</b>	<b>Chair: C H Koehne, DE</b>
30'	The point of view of the pathologist <ul style="list-style-type: none"> <li>- Quality and rules of a good pathology report</li> <li>- Histoprognostic factors: Number of Lymph nodes, neural/lymphatic invasion, lymphocytic infiltration, MSH expression</li> </ul>	Daniela Aust, DE
20'	State-of-the-art: Standard of surgical practice for resectable colorectal cancer (special issues on rectal cancer)	Francis Seow-Choen , SG
30'	State-of-the-art: Standard(s) of perioperative radio/chemotherapy for rectal cancer	Mark Saunders, UK
15'	Discussion	Faculty

10:50-11:10	Coffee Break	
<b>11:10-13:00 105'</b>	<b>Session 2 Adjuvant settings of colorectal cancer</b>	<b>Chair: JY Douillard, FR</b>
30'	Microsatellite instability: Where do we stand? How useful is it?	Daniela Aust, DE
30'	Adjuvant treatment for colon cancer III	Kong Hwai Loong, SG
30'	Adjuvant treatment of stage II Which patients to treat?	CH Koehne
20'	Discussion	Faculty
<b>13:00-14:00 60'</b>	<b>LUNCH</b>	
<b>14:00-14:30 30'</b>	<b>Session 3 Clinical cases</b>	<b>Chair: CH Koehne, DE JY Douillard, FR</b>
30'	2 Clinical cases from participants (10'/case + 5'discussion)	Faculty
<b>14:30-16:15 105'</b>	<b>Session 4: Metastatic colorectal cancer, liver limited metastases</b>	<b>Chair: Francis Seow-Choen, SG</b>
15'	Review of the ESMO consensus conference on metastatic colorectal cancer - Basic strategies and groups (RASwt /mut, BRAF mut)	Jean-Yves Douillard, FR
15'	Development of conventional chemotherapy in mCRC, BSC vs, Chemo, biochemical modulation, oral fluoropyrimidines, development of combination chemotherapy	CH Koehne
30'	Resection of liver limited metastasis (Resectable cases, Group 0) - Upfront - After neo-adjuvant treatment - Repeated hepatectomy	Hauke Lang, DE
30'	Unresectable or borderline resectable (Group 1) chemotherapy +/- targeted agents	CH Koehne, DE
15'	Discussion	Faculty
16:15-16:45	Coffee Break	

### Friday, 27 March 2015, cont.

<b>16:45-18:30 105'</b>	<b>Session 5 Special clinical situations: Mono- or oligometastatic disease</b>	<b>Chair: CH Koehne, DE</b>
30'	Treatment of metastatic disease confined to the peritoneum - Resection - HIPEC - PIPEC	Hauke Lang, DE

30'	Options of locoregional treatment of liver metastasis <ul style="list-style-type: none"> <li>- intraarterial therapy</li> <li>- chemoembolisation</li> <li>- SIRT</li> <li>- Local radiation</li> </ul>	M Ducreux FR
30'	Primary with synchronous metastases	Hauke Lang, DE
15'	Discussion	Faculty

Time TBC	Dinner
----------	--------

## Saturday, 28 May 2014

<b>09:00-10:30 90'</b>	<b>Session 6 Metastatic colorectal cancer I</b>	<b>Chair: CH Koehne, DE</b>
25'	The role of EGFR inhibition in mCRC	Jean-Yves Douillard, FR
25'	The role of VEGF inhibition in mCRC	CH Koehne, DE
10'	Discussion	Faculty
25'	The role of maintenance, appropriate endpoints according to ESMO consensus	M Ducreux FR
5'	Discussion	Faculty

10:30-11:00	Coffee Break
-------------	--------------

<b>11:00-12:15 75'</b>	<b>Session 7 Metastatic colorectal cancer II</b>	<b>Chair: M Ducreux, FR</b>
30'	<ul style="list-style-type: none"> <li>- The Continuum of Care in colorectal cancer versus lines of treatment</li> <li>- Appropriate use of new agents (aflibercept and regorafenib) within the treatment algorithm</li> <li>- Re-introduction of regimens?</li> </ul>	Jean-Yves Douillard, FR
30'	Management of treatment related side effects <ul style="list-style-type: none"> <li>- GI-Toxicity</li> <li>- Neuropathy</li> <li>- Skin toxicity</li> <li>- Hypertension</li> <li>Hand-foot syndrome</li> </ul>	M Ducreux
15'	Discussion	Faculty

<b>12:15-13:00 45'</b>	<b>Session 8 Case presentations from participants followed by panel discussion</b>	<b>Chair: CH Koehne, DE JY Douillard, FR</b>
3X15'	3 Clinical cases from participants (10'/case + 5'discussion)	Faculty

<b>13:00-13:15 15'</b>	<b>Conclusion and farewell</b>	<b>Chair: CH Koehne, DE JY Douillard, FR</b>
13:15-14:00	LUNCH	